Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb;102(2):129-135.
doi: 10.1111/cen.15137. Epub 2024 Oct 3.

Biomarkers and Diagnostic Thresholds for Congenital Hyperinsulinism

Grace Petkovic  1 , Julie Park  1   2 , Catherine Collingwood  3 , Senthil Senniappan  1 , Mohammed Didi  1
Affiliations

Biomarkers and Diagnostic Thresholds for Congenital Hyperinsulinism

Grace Petkovic et al. Clin Endocrinol (Oxf). 2025 Feb.

Abstract

Context: Congenital Hyperinsulinism (CHI) is associated with inappropriately high levels of C-peptide in the context of hypoglycemia.

Objective: We aimed to better clarify a diagnostic threshold value of C-peptide for children presenting with CHI.

Design: This was a retrospective case-control analysis, examining all hypoglycemia screens, undertaken between 2009 and 2019 at a quaternary paediatrics unit. Plasma C-peptide, insulin, free fatty acid (FFA) and B-hydroxybutyrate (BHOB) concentrations in children diagnosed with CHI were compared with concentrations in children diagnosed with other conditions.

Patients: All patients requiring hypoglycaemic screens at the quaternary children's hospital were analysed.

Results: Median [C-peptide] were statistically significantly different between CHI (147) and non-CHI (72) patients, p < 0.05. The Youden Index indicated that a [C-peptide] value of 291.5 pmol/L would give the greatest optimization of sensitivity (82%) and specificity (99%) for detecting CHI. Median [insulin] differed significantly between the cohorts with a level of 64 pmol/L for CHI patients compared with 0 pmol/L with non-CHI patients (p < 0.01). Median [BOHB] was 0 μmol/L in CHI patients as compared with 2378 μmol/L for non-CHI patients (p < 0.01). Median [FFA] levels were 1910 μmol/L in the non-CHI cohort, compared with 0 in the CHI cohort (p < 0.01).

Conclusions: This study suggests that a C-peptide concentration greater than 291.5 pmol/L is diagnostic of CHI in children. C-peptide appears to offer the greatest utility as a biochemical diagnostic test for CHI and could be prioritised for laboratory analysis.

Keywords: C‐peptide; biomarkers; congenital hyperinsulinism; diagnostic tests, routine; hypoglycemia.

PubMed Disclaimer

References

    1. M. J. Dunne, K. E. Cosgrove, R. M. Shepherd, A. Aynsley‐Green, and K. J. Lindley, “Hyperinsulinism in Infancy: From Basic Science to Clinical Disease,” Physiological Reviews 84, no. 1 (January 2004): 239–275, https://doi.org/10.1152/physrev.00022.2003.
    1. T. Meissner, U. Wendel, P. Burgard, S. Schaetzle, and E. Mayatepek, “Long‐Term Follow‐Up of 114 Patients With Congenital Hyperinsulinism,” European Journal of Endocrinology 149, no. 1 (July 2003): 43–51, https://doi.org/10.1530/eje.0.1490043.
    1. F. Menni, P. de Lonlay, C. Sevin, et al., “Neurologic Outcomes of 90 Neonates and Infants With Persistent Hyperinsulinemic Hypoglycemia,” Pediatrics 107, no. 3 (March 2001): 476–479, https://doi.org/10.1542/peds.107.3.476.
    1. A. Ludwig, K. Ziegenhorn, S. Empting, et al., “Glucose Metabolism and Neurological Outcome in Congenital Hyperinsulinism,” Seminars in Pediatric Surgery 20, no. 1 (February 2011): 45–49, https://doi.org/10.1053/j.sempedsurg.2010.10.005.
    1. H. Demirbilek and K. Hussain, “Congenital Hyperinsulinism: Diagnosis and Treatment Update,” Journal of Clinical Research in Pediatric Endocrinology 9, no. Suppl 2 (December 2018): 69–87, https://doi.org/10.4274/jcrpe.2017.S007.

LinkOut - more resources